Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294047 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,752
- Enrollment target
NCT00294047 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 5,752 participants.
The verdict
NCT00294047, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,752 participants
- Enrollment target
Study Summary
This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control. Under Protocol Amendment 3, study participation will last approximately 48 months and involves a total of eleven scheduled visits. Under Protocol Amendment 4, study participation will last up to 84 months and involves a maximum of seventeen scheduled visits.
Interventions
- BIOLOGICAL Cervarix
- BIOLOGICAL Placebo control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,752 participants |
| Start Date | 2006-02-16 |
| Est. Completion | 2014-01-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294047
The ClinicalTrials.gov registry entry for NCT00294047 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,752 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cervarix is the first listed.
NCT00294047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294047 about?
NCT00294047 is a clinical study titled "Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older". This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control. Under Protocol Amendment 3, study participation will last approximately 48 months and involves a total of eleven scheduled visits. Under Protocol Amendment 4, study pa...
What is the current status of trial NCT00294047?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,752 participants. The study started on 2006-02-16. Estimated completion is 2014-01-29.
What interventions are being tested in trial NCT00294047?
The interventions under investigation include: Cervarix (BIOLOGICAL), Placebo control (BIOLOGICAL).
Who is sponsoring clinical trial NCT00294047?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.